ASAdam M. Syanda

Adam M. Syanda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adam M. Syanda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Dimitra Georgantaki

    Department of Metabolism, Digestion and Reproduction, Faculty of Medicine Imperial College London London UK

    2 shared publications
  • Mariam Molokhia

    Department of Population Health Sciences School of Life Course and Population Sciences, King's College London London UK

    2 shared publications
  • Sheikh Tamir Rashid

    Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

    2 shared publications
  • Amara Agbai

    Faculty of Medicine Imperial College London London UK

    1 shared publication
  • Armando E. del Río Hernández

    Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Imperial College London, UK

    1 shared publication
  • Dariusz Lachowski

    Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Imperial College London, UK

    1 shared publication

Latest Publications

  • Open Access

    Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency

    by Adam M. Syanda, Dimitra Georgantaki, Riona T. T. Linn, Amara Agbai, Hassan Tahir, Manako Sakai, Richard Thompson, Mariam Molokhia, S. Tamir Rashid

    Background: Heterozygous SERPINA1 genotypes (MZ, SZ) have historically been regarded as carrier states with limited liver relevance. Emerging evidence suggests increased liver injury, but the magnitude of risk remains uncertain. We synthesized evidence on heterozygous SERPINA1 liver phenotypes to quantify this risk. Methods: We performed a systematic review of bibliographic databases from inception to 21 October 2025 for studies reporting liver outcomes in MZ or SZ genotypes. Outcomes were grouped into metabolic comorbidities, biochemical markers, and clinical liver disease. Random‐effects meta‐analyses pooled mean differences (MDs) and odds ratios (ORs); risk of bias was assessed with established tools (PROSPERO CRD420251165586). Results: Twenty‐six studies including 27,933 heterozygotes and 547,961 controls met inclusion criteria. BMI (MD −0.09 [−0.20–0.02]) and steatosis risk (OR 1.09 [0.74–1.60]) were comparable between groups. Heterozygotes had modestly higher liver enzymes (ALT MD 1.03 [0.41–1.66]; AST MD 0.68 [0.51–0.85]; ALP MD 2.58 [1.58–3.58]) and higher odds of abnormal ALT (OR 1.18 [1.11–1.25]), AST (OR 1.16 [1.07–1.26]), and ALP (OR 1.41 [1.18–1.68]). They had significantly increased odds of fibrosis (OR 2.14 [1.52–3.02]), cirrhosis (OR 2.24 [1.73–2.91]), and liver transplantation (OR 2.28 [1.45–3.59]). Conclusions: Heterozygous SERPINA1 genotypes are bona fide liver risk states, with effect sizes comparable to established genetic and environmental determinants. MZ / SZ heterozygosity should be recognized as moderate‐penetrance liver susceptibility genotypes in chronic liver disease risk assessment.


  • Open Access

    Liver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha‐1 Antitrypsin Deficiency—A Meta‐Analysis

    by Adam M. Syanda, Dimitra Georgantaki, Muhammad Awsaf, Mariam Molokhia, S. Tamir Rashid

    Alpha‐1 antitrypsin deficiency (A1ATD) is an inherited metabolic disorder caused by a mutation (ZZ) in the SERPINA1 gene. Carriers are predisposed to liver and lung pathology. The severity of A1ATD‐associated liver disease is highly variable, necessitating further characterisation. This study aims to investigate the risk and extent of liver disease and the prevalence of liver transplantation in ZZ A1ATD patients. Several established databases, including Ovid, EBSCO, PubMed, and Cochrane Library, were searched from inception to May 12, 2024. Data were pooled using a random effects model, and study weight was calculated using the inverse variance method. Crude odds ratios (cOR) were calculated using participants with the MM genotype as the comparator. The study was registered in PROSPERO (CRD42022335666). Of the 4420 studies identified, 45 studies and 8638 A1ATD patients (38.8% female) were included. ZZ A1ATD patients demonstrate an increased risk of liver diseases compared to controls, including steatosis (crude odds ratio (cOR): 1.52 [95% CI: 1.21, 1.91]), fibrosis (cOR: 9.85 [95% CI: 5.70, 17.03]), cirrhosis (cOR: 10.43 [95% CI: 5.51, 19.73]), and liver cancers (cOR: 14.12 [95% CI: 6.50, 30.66]). The prevalence of liver transplantation is considerable, with rates reaching 5% [95% CI: 0.00, 12.34]. Our findings confirm the substantial burden of liver disease in ZZ A1ATD patients, including subclinical manifestations such as steatosis and fibrosis that may remain undetected. Given the lack of approved treatments for A1ATD‐associated liver disease, prioritising the development of novel therapies to stop or reverse liver disease is essential.


  • Open Access

    RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling

    by Samuel J.I. Blackford, Tracy T.L. Yu, Michael D.A. Norman, Adam M. Syanda, Michail Manolakakis, Dariusz Lachowski, Ziqian Yan, Yunzhe Guo, Elena Garitta, Federica Riccio, et al.